Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$883.05 USD

883.05
344,687

-2.50 (-0.28%)

Updated Oct 4, 2024 10:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eli Lilly (LLY) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 12.93% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

by Zacks Equity Research

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.

Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.

Thermo Fisher (TMO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

The negative impact of COVID-19 in the form of supply issues and staffing shortages are expected to have deterred growth in a few areas within the Analytical Instruments business of Thermo Fisher (TMO).

The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals

by Zacks Equity Research

Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.

Eli Lilly (LLY) Stock Moves -1.13%: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $289.61 in the latest trading session, marking a -1.13% move from the prior day.

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy

by Kinjel Shah

Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.

Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.

AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag

by Zacks Equity Research

FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).

Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA

by Zacks Equity Research

Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.

Has Brickell Biotech (BBI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Brickell (BBI) and Eli Lilly (LLY) have performed compared to their sector so far this year.

J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View

by Zacks Equity Research

J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.

Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months

by Zacks Equity Research

Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.

Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures

by Zacks Equity Research

Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.

J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.

Neena Mishra headshot

Healthcare ETFs Outperform Amid Rising Uncertainties

by Neena Mishra

Investors are seeking refuge in healthcare stocks as inflation and rates rise

Eli Lilly (LLY) Stock Moves -0.88%: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $308.96 in the latest trading session, marking a -0.88% move from the prior day.

Sheraz Mian headshot

Top Analyst Reports for Alphabet, Amazon & AbbVie

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV).

Ekta Bagri headshot

Antibody Treatments for COVD-19 Face Challenges in the U.S.

by Ekta Bagri

With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.

Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm

by Zacks Equity Research

Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.

VIR Stock Down on Another Setback for COVID-19 Antibody

by Zacks Equity Research

VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.

If You Invested $1000 in Eli Lilly 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $292.49 in the latest trading session, marking a +0.37% move from the prior day.